PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012

PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012

March 30, 2012 at 12:00 AM EDT

WALTHAM, Mass. – March 30, 2012 – At the American Association for Cancer Research 2012 Annual Meeting (Booth #2306), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will be showcasing numerous solutions, posters and knowledge-sharing events in support of cancer-focused personalized medicine research.

"PerkinElmer remains committed to the fight against cancer through enabling personalized medicine solutions that allow researchers to find, understand, and act upon the causes and processes of the disease,” said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer.  “We are passionate about helping academic, biopharma and clinical researchers to achieve new insights for discovering advanced therapeutics and diagnostics to reduce the threat of cancer.  Our solutions in Next Generation Sequencing, advanced cellular, in vitro and in vivo imaging, automation instrumentation, and reagent technologies, provide researchers the critical tools they need to combat this deadly disease."

On the evening of Tuesday, April 3, PerkinElmer will be hosting an event, entitled

"The Revolutionizing Medicine Rock 'n' Roll Reception," featuring distinguished speakers who are committed to the fight against cancer, discussing how personalized medicine is changing research and treatment of the disease.  The event will also feature performances by Molecular Groove, the PerkinElmer band.

  • Tuesday, April 3, 6:30 PM – 10:30 PM
  • Hyatt Regency McCormick Place, Regency Ballroom

Featured speakers at the event include clinical, academic and industry thought leaders in personalized medicine for cancer, such as:

  • Raju Kucherlapati Ph.D., Professor of Genetics and Medicine, Harvard University, who will speak on “Personalized Medicine in Cancer”
  • James P. Basilion, Ph.D., Associate Professor, Departments of Radiology, Biomedical Engineering, and Pathology, Case Western Reserve University, whose discussion topic is  “Defining the Cutting Edge”
  • Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, who will present on “Next Generation Innovations Enabling an Advancement in Health”

PerkinElmer solutions for enabling personalized medicine-based cancer research on display at AACR 2012 include:

  • The NGS Express™ Automated Liquid Handling Workstation - a compact flexible and easy-to-use library prep system for benchtop sequencers that offers efficient sample preparation for up to 24 Next Generation Sequencing libraries, and eliminates the need for time-consuming protocol development.  
  • FolateRSense™ and TLectinSense™ Fluorescent Preclinical Imaging Agents, designed to be used by in vivo imaging systems, and for the quantitation and longitudinal study of tumor growth and vascularization.
  • AlphaLISA® cellular epigenetics detection kits, a no-wash homogeneous proximity immunoassay to detect specific methylation and acetylation states for epigenetics research.

PerkinElmer instruments and software featured at AACR include:

PerkinElmer poster presentations at AACR 2012 include:

  • Sunday, April 1: 1:00 pm – 5:00 pm
    • 236/30 Hall F, Section 8 Characterizing cellular signal transduction cross-talk using in-cell kinase screen
    • 382/30 Hall F, Section 13 In-vivo imaging of lung cancer using tumor homing peptide coated nanoparticles
  • Monday, April 2: 8:00 am – 12:00 pm
    • 1319/6 Hall F, Section 11 Establishment & characterization of fresh primary human colorectal tumor implants
  • Monday, April 2: 1:00 pm – 5:00 pm
    • 2448/21 Hall F, Section 16 Development of a red fluorescent labeled agent for assessing HER2 expression in vitro & in vivo
    • 2444/17 Hall F, Section 16 Non-invasive FMT quantification of folate receptor expression in mouse tumor xenografts with a new near-infrared fluorescent folate agent
  • Tuesday, April 3: 8:00 am – 12:00 pm
    • 3879/2 Hall F, Section 34 High-throughput, homogeneous in cyto assays to monitor histone H3 post-translational modifications
    • 3880/3 Hall F, Section 34 Application of tyramide signal amplification technology to high content analysis of cellular kinase translocation assays
  • Tuesday, April 3: 1:00 pm – 5:00 pm
    • 3949/16 Hall F, Section 1 In vivo imaging of tumor hypoxia by a new near-infrared fluorescent carbonic anhydrase IX-targeted agent
    • 4292/8 Hall F, Section 14 In vivo & in vitro imaging of Cyclooxygenase-2 in tumor
    • 4050/5 Hall F, Section 5 Monitoring of melanoma therapy with quantitative tissue cytometry of a panel of apoptosis markers
  • Wednesday, April 4: 8:00 am – 12:00 pm
    • LB-511 Hall F, Section 38 In vivo imaging of tumor vasculature with a novel near infra-red lectin agent

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

# # #

Media Contacts:

Mario Fante
Corporate Public Relations Manager
Phone: (781) 663-5602
Email:  mario.fante@perkinelmer.com

Amanda L. Connolly
Edelman (on behalf of PerkinElmer, Inc.)
Direct:   (404) 832-6785
Email:    amanda.connolly@edelman.com

Related Links

IR Contact

ir@perkinelmer.com
(781) 663 - 6900
940 Winter Street
Waltham, MA 02451
United States
www.perkinelmer.com

Transfer Agent

Mailing addresses
Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY 40233

Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Shareholder website www.computershare.com/investor
Shareholder online inquiries
www-us.computershare.com/investor/Contact